News

Contribute towards the global effort to combat antibiotic resistance.

Allecra has one product candidate in Phase 1 clinical trials and another more advanced product candidate in Phase 2 trials. Each of Allecra’s two product candidates is designed to have a unique spectrum of activity and is clearly differentiated from current treatment options and from competitors’ development pipelines

Allecra Therapeutics Strengthens Leadership Team with Appointment of New Chairman and Chief Medical Officer

Lörrach, Germany and Saint Louis, France – Allecra Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, announced today two key appointments to significantly strengthen Allecra’s leadership team as the Company enters its next phase of development. Dr. Engelbert (Bert) Tjeenk Willink is appointed to the position…

Find out more

Allecra Therapeutics Announces €22 Million Series B Financing

Funding Supports Phase 2 Development of Novel Antibiotic to Treat Resistant Gram-negative Bacterial Infections in the Hospital Lörrach, Germany and Saint Louis, France – Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, announced today the closing of its €22 Million Series B investment round. The round…

Find out more

New Anti-infectives Company, Allecra Therapeutics, created with €15 million Series A Financing

Lörrach, Germany and Saint Louis, France – The creation of Allecra Therapeutics, a new company joining the established European BioValley Life Sciences cluster, was announced today. Allecra is a biopharmaceutical company dedicated to the development of novel antibiotics to combat multi drug-resistant bacterial infections. Allecra’s €15 million Series A financing round was co-led by Edmond…

Find out more
""